Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analys...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Dimopoulos, Meletios, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, San-Miguel, Jesus, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Casal, Eva, Srinivasan, Shankar, Yu, Xin, Nguyen, Tuong Vi, Biyukov, Tsvetan, Peluso, Teresa, Richardson, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8179841/
https://ncbi.nlm.nih.gov/pubmed/32895455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01021-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados